Etanercept Biosimilars Pipeline Insights | 15+ Companies, Including Sandoz, Lupin, and Shilpa Biologicals, Spearheading the Next Wave of Innovation

The Etanercept Biosimilars market is evolving with cutting-edge research and new therapeutic advancements.

DelveInsight's 'Etanercept Biosimilars Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Etanercept Biosimilars therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Etanercept Biosimilars pipeline domain.

For Etanercept Biosimilars emerging drugs, the Etanercept Biosimilars pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Etanercept Biosimilars Pipeline Report
• DelveInsight's Etanercept Biosimilars Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline drugs for Etanercept Biosimilars treatment.
• The leading Etanercept Biosimilars companies include Sandoz, Lupin, Intas Biopharmaceuticals, Merck & Co. / Samsung Bioepis, AryoGen Pharmed, Rus Biopharm, Shanghai Celgen, and others are evaluating their lead assets to improve the Etanercept Biosimilars treatment landscape.
• Key Etanercept Biosimilars pipeline therapies in various stages of development include SBDM-01, and others.
• In May 2024, Lupin, through its partner Sandoz Canada, is launching Rymti, its first biosimilar in Canada. Rymti, an etanercept biosimilar, was approved by Health Canada in August 2022 for all indications of the reference product Enbrel.

Request a sample and discover the recent breakthroughs happening in the Etanercept Biosimilars pipeline landscape @ https://www.delveinsight.com/report-store/etanercept-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Etanercept Biosimilars Overview
Etanercept is prescribed for the treatment of moderately to severely active rheumatoid arthritis in adults, as well as chronic moderate to severe plaque psoriasis in patients aged four years and older. It is also indicated for managing the signs and symptoms of polyarticular idiopathic arthritis in individuals aged two years and older.

Additionally, etanercept is used to alleviate symptoms associated with psoriatic arthritis and ankylosing spondylitis. It is a dimeric fusion protein comprising the extracellular ligand-binding segment of the human 75-kilodalton (p75) tumor necrosis factor receptor (TNFR) fused to the Fc portion of human IgG1. The Fc region of etanercept includes the CH2 and CH3 domains along with the hinge region, but it lacks the CH1 domain of IgG1. Produced using recombinant DNA technology in a Chinese hamster 0vary (CHO) mammalian cell expression system, etanercept consists of 934 amino acids. It is widely utilized for managing inflammatory conditions such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic polyarticular arthritis (JIA).

Find out more about Etanercept Biosimilars medication @ https://www.delveinsight.com/report-store/etanercept-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Etanercept Biosimilars Treatment Analysis: Drug Profile
SBDM-01: Shilpa Biologicals
Shilpa Biologicals is developing an etanercept biosimilar, SBDM-01, which is currently under clinical development. The drug candidate acts by targeting tumor necrosis factor (TNFR) receptor. The biosimilar is being studied in the Phase I stage of Clinical trial evaluation for the treatment of various autoimmune diseases, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.

Key Etanercept Biosimilars Therapies and Companies
• SBDM-01: Shilpa Biologicals

Learn more about the novel and emerging Etanercept Biosimilars pipeline therapies @ https://www.delveinsight.com/report-store/etanercept-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Etanercept Biosimilars Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Marketed stage products
• Late stage products (BLA Filed and Phase III)
• Mid-stage products (Phase II and
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Subcutaneous
• Intravenous

By Molecule Type
• Monoclonal antibodies
• Peptide
• Protein
• Small molecule

Scope of the Etanercept Biosimilars Pipeline Report
• Coverage: Global
• Key Etanercept Biosimilars Companies: Sandoz, Lupin, Intas Biopharmaceuticals, Merck & Co. / Samsung Bioepis, AryoGen Pharmed, Rus Biopharm, Shanghai Celgen, and others.
• Key Etanercept Biosimilars Pipeline Therapies: SBDM-01, and others.

Dive deep into rich insights for drugs used for Etanercept Biosimilars treatment; visit @ https://www.delveinsight.com/report-store/etanercept-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Etanercept Biosimilars Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Etanercept Biosimilars Pipeline Therapeutics
6. Etanercept Biosimilars Pipeline: Late-Stage Products (Phase III)
7. Etanercept Biosimilars Pipeline: Late-Stage Products (Phase III)
8. Etanercept Biosimilars Pipeline: Mid-Stage Products (Phase II)
9. Etanercept Biosimilars Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.